Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar;43(3):1755-1759.
doi: 10.1007/s10072-021-05579-3. Epub 2021 Aug 29.

Serum levels of lipocalin-2 in patients with Parkinson's disease

Mi Xiong  1 , Qian Qian  1 , Xue Liang  1 , You-Dong Wei  2   3
Affiliations

Serum levels of lipocalin-2 in patients with Parkinson's disease

Mi Xiong et al. Neurol Sci. 2022 Mar.

Abstract

Background: Parkinson's disease (PD) is the second most common neurodegenerative disease. Evidence has shown that lipocalin-2 (LCN2) is involved in the pathological process of PD. We aimed to explore whether serum levels of LCN2 could be a biomarker of PD.

Methods: We recruited consecutive PD patients and healthy controls (HC) in our hospital from June 2020 to July 2020. Serum LCN2 levels were detected using the LCN2 enzyme-linked immunosorbent assay (ELISA) kit. The motor section of the Unified Parkinson's Disease Rating Scale (UPDRS III) and the Hoehn and Yahr Staging Scale (H&Y) were assessed on admission to evaluate disease severity in patients with PD. Cognitive status was measured by the Montreal Cognitive Assessment (MoCA).

Results: We finally recruited 75 patients, including 40 PD patients and 35 HC. Serum LCN2 levels were not significantly increased in PD patients compared with HC (4.9 [- 0.7 to 18.6] vs 1.9 [- 1.5 to 16.9] ng/mL, P = 0.33). Besides, there was no significant difference in LCN2 levels between patients at early and advanced stage of PD (P = 0.75), as well as between cognitively impaired PD patients, PD patients with normal cognition, and HC (P = 0.30). Moreover, LCN2 had no correlation with disease duration (r = - 0.1, P = 0.37), UPDRS III score (r = 0.07, P = 0.65), and MoCA score (r = 0.221, P = 0.17).

Conclusions: Overall, our study suggests that serum LCN2 levels may not be a biomarker for PD.

Keywords: Biomarker; Cognitive impairment; Inflammation; Lipocalin-2; NGAL; Parkinson’s disease.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Kalia LV, Lang AE (2015) Parkinson’s disease. Lancet (London, England) 386(9996):896–912. https://doi.org/10.1016/s0140-6736(14)61393-3 - DOI
    1. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30(12):1591–1601. https://doi.org/10.1002/mds.26424 - DOI - PubMed - PMC
    1. Pfeiffer RF (2016) Non-motor symptoms in Parkinson’s disease. Parkinsonism Relat Disord 22(Suppl 1):S119-122. https://doi.org/10.1016/j.parkreldis.2015.09.004 - DOI - PubMed
    1. Braak H, Del Tredici K (2017) Neuropathological staging of brain pathology in sporadic Parkinson’s disease: separating the wheat from the chaff. J Parkinsons Dis 7(s1):S71–S85. https://doi.org/10.3233/jpd-179001 - DOI - PubMed - PMC
    1. Tansey MG, Goldberg MS (2010) Neuroinflammation in Parkinson’s disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 37(3):510–518. https://doi.org/10.1016/j.nbd.2009.11.004 - DOI - PubMed

LinkOut - more resources